{"nctId":"NCT03489941","briefTitle":"A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor速 (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle","startDateStruct":{"date":"2018-04-07","type":"ACTUAL"},"conditions":["Allergic Conjunctivitis"],"count":65,"armGroups":[{"label":"EM-100","type":"EXPERIMENTAL","interventionNames":["Drug: EM-100"]},{"label":"Zaditor速","type":"EXPERIMENTAL","interventionNames":["Drug: Zaditor速"]},{"label":"Vehicle","type":"EXPERIMENTAL","interventionNames":["Drug: Vehicle"]}],"interventions":[{"name":"EM-100","otherNames":[]},{"name":"Zaditor速","otherNames":[]},{"name":"Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* be at least 18 years old\n* have a positive history of allergic conjunctivitis and positive skin test reaction to allergens\n* be willing to avoid disallowed medications for the appropriate washout period and throughout the trial\n* be willing to avoid contact lens use\n* be willing to have a pregnancy test\n* must be able to read an eye chart from 10 feet away\n\nExclusion Criteria:\n\n* must not have any allergies to the study medications\n* must not have any ocular or non ocular condition that investigator feels will interfere with study parameters\n* must not have used an investigational drug or device in the past 30 days or currently be enrolled in another investigational trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ocular Itching","description":"Ocular itching scores were self-assessed by the participant using a 5-point scale with 0.5 unit increments, wherein 0 = None (normal, no itching), 1.0 = Intermittent tickle sensation involving more than just the corner of the eye, 2.0 = Mild continuous itch without desire to rub, 3.0 = Severe itch with desire to rub, and 4.0 = Incapacitating itch with irresistible urge to rub.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.81","spread":"0.787"},{"groupId":"OG001","value":"0.79","spread":"0.750"},{"groupId":"OG002","value":"1.98","spread":"0.935"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.09","spread":"1.047"},{"groupId":"OG001","value":"1.04","spread":"0.989"},{"groupId":"OG002","value":"2.17","spread":"1.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","spread":"1.103"},{"groupId":"OG001","value":"1.04","spread":"1.047"},{"groupId":"OG002","value":"2.22","spread":"1.032"}]}]}]},{"type":"SECONDARY","title":"Conjunctival Redness","description":"The investigator assessed conjunctival redness scores using a 5-point scale with 0.5 unit increments, wherein 0 = None (normal, no dilated blood vessels), 1 = Mild (slightly dilated blood vessels: pink color; can be quadrantal), 2 = Moderate (more apparent dilation, with redder color, involving majority of the vessel bed), 3 = Severe (numerous and obvious dilated blood vessels, with deep red color and no color, or less red with chemosis), and 4 = Extremely Severe (large, numerous, dilated blood vessels characterized by unusually severe deep red color regardless of chemosis and involving the entire vessel bed).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.13","spread":"0.824"},{"groupId":"OG001","value":"2.14","spread":"0.743"},{"groupId":"OG002","value":"2.72","spread":"0.725"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.25","spread":"0.783"},{"groupId":"OG001","value":"2.29","spread":"0.737"},{"groupId":"OG002","value":"2.61","spread":"0.847"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.16","spread":"0.857"},{"groupId":"OG001","value":"2.24","spread":"0.704"},{"groupId":"OG002","value":"2.46","spread":"0.784"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":65},"commonTop":[]}}}